Alliance Entertainment Azioni (NASDAQ: AENT)

Ultime notizie per Alliance Entertainment (NASDAQ:AENT) Azioni

Alliance Entertainment

Alliance Entertainment Holding Corp is a top-tier distributor of music, movies, and consumer electronics. It offers products consisting of vinyl records, compact discs, DVDs, Blu-rays, and video games. The company serves customers of every size, providing a suite of services to resellers and retailers around the world.

Alliance Entertainment Holding Corporation - common stock

Alliance Entertainment Holding Corp

Alliance Entertainment Holding Corporation - Warrants

News

KNDI

Kandi Technologies  Announces collaboration With Hangzhou Yunshenchu Technology To combined Manufacturing, Technical And Channel Capabilities Fo Co-Develop Smart Golf Equipment And Security Inspection Robots

<p>Booking Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) today announced an eight-year extension of Booking.com's existing and long-standing commercial partnership with Etraveli Group, building on a successful collaboration first established in 2019. This renewed commitment will further strengthen and accelerate Booking.com's efforts to build a seamless, scalable global flights offering, which is live in 57 countries today, and reflects both companies' ambition to deliver more ease, choice, and value to travelers and partners worldwide.</p>


BKNG

Booking Holdings Announces 8-Yr Extension Of Booking.com's Existing Commercial Partnership With Etraveli Group

<p>Oppenheimer  analyst Rayna Kumar   initiates coverage on Sezzle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEZL#NASDAQ">SEZL</a>) with a Outperform rating and announces Price Target of $168.</p>


Price Target

Initiation

Analyst Ratings

SEZL

Oppenheimer Initiates Coverage On Sezzle with Outperform Rating, Announces Price Target of $168

<p>Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.</p>
<ul class="wp-block-list">
<li>Barclays raised<strong> Victoria&#8217;s Secret &amp; Co.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) price target from $22 to $23. Barclays analyst Adrienne Yih maintained an Overweight rating. Victoria&#8217;s Secret shares closed at $21.00 on Wednesday. <a href="https://www.benzinga.com/quote/vsco/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>WestPark Capital increased the price target for <strong>Oracle Corporation</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) from $195 to $246. WestPark Capital analyst Curtis Shauger maintained a Buy rating. Oracle shares closed at $176.38 on Wednesday. <a href="https://www.benzinga.com/quote/ORCL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. raised <strong>Exelixis, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) price target from $40 to $47. HC Wainwright &amp; Co. analyst Robert Burns maintained a Buy rating. Exelixis shares closed at $41.43 on Wednesday. <a href="https://www.benzinga.com/quote/EXEL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rosenblatt raised the price target for <strong>Fabrinet </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) from $250 to $290. Rosenblatt analyst Mike Genovese maintained a Buy rating. Fabrinet shares closed at $243.20 on Wednesday. <a href="https://www.benzinga.com/quote/FN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Telsey Advisory Group slashed the price target for<strong> J.Jill, Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JILL#NYSE">JILL</a>) from $21 to $17. Telsey Advisory Group analyst Dana Telsey maintained a Market Perform rating. J.Jill shares closed at $14.13 on Wednesday. <a href="https://www.benzinga.com/quote/JILL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Rosenblatt raised <strong>Calix, Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CALX#NYSE">CALX</a>) price target from $52 to $56. Rosenblatt analyst Mike Genovese maintained a Buy rating. Calix shares settled at $47.88 on Wednesday. <a href="https://www.benzinga.com/quote/calx/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities raised <strong>DoorDash, Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) price target from $230 to $245. B of A Securities analyst Michael McGovern maintained a Buy rating. DoorDash shares closed at $217.80 on Wednesday. <a href="https://www.benzinga.com/quote/dash/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stephens &amp; Co. increased <strong>Darden Restaurants, Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) price target from $178 to $200. Stephens &amp; Co. analyst Jim Salera maintained an Equal-Weight rating. Darden Restaurants shares closed at $217.67 on Wednesday.  <a href="https://www.benzinga.com/quote/dri/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank cut the price target for <strong>United Natural Foods, In</strong>c. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNFI#NYSE">UNFI</a>) from $33 to $24. Deutsche Bank analyst Krisztina Katai maintained a Hold rating. United Natural Foods shares settled at $22.13 on Wednesday. <a href="https://www.benzinga.com/quote/unfi/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays raised <strong>Dana Incorporated </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAN#NYSE">DAN</a>) price target from $20 to $25. Barclays analyst Dan Levy maintained an Overweight rating. Dana shares closed at $17.71 on Wednesday. <a href="https://www.benzinga.com/quote/DAN/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
<p>Considering buying DASH stock? Here&#8217;s what analysts think: </p>
<p><figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/DASH/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="588" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12090110/image-195-1024x588.png" alt="" class="wp-image-947647" style="width:669px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12090110/image-195-1024x588.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12090110/image-195-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12090110/image-195-768x441.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/12090110/image-195.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure></p>
<p><strong>Read This Next: </strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45882911/top-2-consumer-stocks-that-may-plunge-in-june">Top 2 Consumer Stocks That May Plunge In June</a></strong> </li>
</ul>
<p>Photo via Shutterstock</p>


Markets

Trading Ideas

CALX

DASH

EXEL

JILL

ORCL

UNFI

VSCO

DoorDash To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Thursday

<p><i>With this renewal, eligible shoppers can now select Affirm's biweekly or monthly payment plans directly at checkout on DICKS.com or GolfGalaxy.com</i></p>
<p>Today, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.dickssportinggoods.com%2F&amp;esheet=54273063&amp;newsitemid=20250612145092&amp;lan=en-US&amp;anchor=DICK%26%238217%3BS+Sporting+Goods&amp;index=1&amp;md5=7ed745fb276fc81516d41068d39225fc">DICK'S Sporting Goods</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>), a leading U.S. based full-line omni-channel sporting goods retailer, and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.affirm.com%2F&amp;esheet=54273063&amp;newsitemid=20250612145092&amp;lan=en-US&amp;anchor=Affirm&amp;index=2&amp;md5=7ba735235499cd0bc62db4dc4379ddea">Affirm</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>), the payment network that empowers consumers and helps merchants drive growth, announced an extension of their partnership, which originally began in 2020. Just in time for the summer adventure season, eligible DICK'S and Golf Galaxy shoppers can now choose Affirm's flexible, transparent payment plans when checking out directly on <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2FDICKS.com&amp;esheet=54273063&amp;newsitemid=20250612145092&amp;lan=en-US&amp;anchor=DICKS.com&amp;index=3&amp;md5=96b6ddac3b293ebd2e8221bb8c784b0c">DICKS.com</a> or <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2FGolfGalaxy.com&amp;esheet=54273063&amp;newsitemid=20250612145092&amp;lan=en-US&amp;anchor=GolfGalaxy.com&amp;index=4&amp;md5=b180b234eac142e8b6fd920f12521ccd">GolfGalaxy.com</a>.</p>


AFRM

DICK'S Sporting Goods And Affirm Extend Partnership, Enhancing Flexible Payment Options

Offerings

DoubleDown Interactive Announces Pricing Of Secondary 4,347,827 ADS Offering By Selling Shareholder At $8.50 Per ADS

<p>7 analysts have expressed a variety of opinions on Dana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAN#NYSE">DAN</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Dana, revealing an average target of $19.29, a high estimate of $25.00, and a low estimate of $15.00. Surpassing the previous average price target of $17.71, the current average has increased by 8.92%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1749733301_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Dana by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dan Levy</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Tom Narayan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$20.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Colin Langan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Dan Levy</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Joseph Spak</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$20.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Dan Levy</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$17.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Joseph Spak</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$18.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Dana. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Dana compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Dana's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Dana's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DAN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Dana analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Dana</h2>
<p>Dana Inc is engaged in the designing and manufacturing of efficient propulsion and energy-management solutions that power vehicles and machines in all mobility markets across the globe. The company has four operating segments: Light Vehicles, Power Technologies, Commercial Vehicle, and Off-Highway. The Light Vehicles segment generates the majority portion of revenue by providing products to support light vehicle OEMs. Its products are designed for light trucks, SUVs, CUVs, vans, and passenger cars.</p>
<h3>Dana's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Decline in Revenue:</strong> Over the 3M period, Dana faced challenges, resulting in a decline of approximately <strong>-14.0%</strong> in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Dana's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>1.06%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Dana's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>1.84%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>0.33%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>2.23</strong>, Dana faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Assessing Dana: Insights From 7 Financial Analysts

<p>In the last three months, 5 analysts have published ratings on TeraWulf (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $5.0, a high estimate of $7.00, and a low estimate of $4.00. Highlighting a 21.01% decrease, the current average has fallen from the previous average price target of $6.33. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1749733282_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The analysis of recent analyst actions sheds light on the perception of TeraWulf by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chris Brendler</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$6.00</td>
<td>$4.50</td>
</tr>
<tr>
<td>Greg Miller</td>
<td>JMP Securities</td>
<td>Announces</td>
<td>Market Outperform</td>
<td>$7.00</td>
<td>-</td>
</tr>
<tr>
<td>Chris Brendler</td>
<td>Rosenblatt</td>
<td>Lowers</td>
<td>Buy</td>
<td>$4.00</td>
<td>$4.50</td>
</tr>
<tr>
<td>Chris Brendler</td>
<td>Rosenblatt</td>
<td>Lowers</td>
<td>Buy</td>
<td>$4.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Stephen Glagola</td>
<td>Jones Trading</td>
<td>Announces</td>
<td>Buy</td>
<td>$4.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to TeraWulf. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of TeraWulf compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into TeraWulf's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/WULF/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on TeraWulf analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About TeraWulf</h2>
<p>TeraWulf Inc is a digital asset technology company that is engaged in digital infrastructure and sustainable energy development. It is involved in supporting environmentally conscious bitcoin mining operations by developing and operating facilities within the United States. The company's bitcoin mining facilities are powered by clean, affordable, and reliable energy sources. Its primary source of revenue stems from the mining of bitcoin conducted at the company's mining facility sites. Additionally, the company occasionally generates revenue through the provision of miner hosting services to third-party entities.</p>
<h3>TeraWulf: Financial Performance Dissected</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Negative Revenue Trend:</strong> Examining TeraWulf's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately <strong>-18.92%</strong> in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> TeraWulf's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>-178.51%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> TeraWulf's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-31.0%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> TeraWulf's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-7.54%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> TeraWulf's debt-to-equity ratio surpasses industry norms, standing at <strong>3.05</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


WULF

The Analyst Verdict: TeraWulf In The Eyes Of 5 Experts

<p>4 analysts have shared their evaluations of NewAmsterdam Pharma Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAMS#NASDAQ">NAMS</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $41.5, a high estimate of $44.00, and a low estimate of $40.00. This current average reflects an increase of 0.41% from the previous average price target of $41.33. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1749733265_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>A comprehensive examination of how financial experts perceive NewAmsterdam Pharma Co is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>James Condulis</td>
<td>Stifel</td>
<td>Announces</td>
<td>Buy</td>
<td>$44.00</td>
<td>-</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$40.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to NewAmsterdam Pharma Co. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of NewAmsterdam Pharma Co compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of NewAmsterdam Pharma Co's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of NewAmsterdam Pharma Co's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/NAMS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on NewAmsterdam Pharma Co analyst ratings.</strong></a></p>
<h2>About NewAmsterdam Pharma Co</h2>
<p>NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.</p>
<h3>Key Indicators: NewAmsterdam Pharma Co's Financial Health</h3>
<p><strong>Market Capitalization:</strong> Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.</p>
<p><strong>Revenue Growth:</strong> NewAmsterdam Pharma Co displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately <strong>112.56%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> NewAmsterdam Pharma Co's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-1327.3%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> NewAmsterdam Pharma Co's ROE excels beyond industry benchmarks, reaching <strong>-5.15%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-4.7%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.0</strong>.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


NAMS

What Analysts Are Saying About NewAmsterdam Pharma Co Stock

<p>Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Genius Sports (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GENI#NYSE">GENI</a>) in the last three months.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $12.67, along with a high estimate of $14.00 and a low estimate of $12.00. Observing a 3.43% increase, the current average has risen from the previous average price target of $12.25. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1749733252_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Genius Sports. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$13.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>David Bain</td>
<td>Texas Capital Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$14.00</td>
<td>-</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$13.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Clark Lampen</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$12.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Mike Hickey</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Curry Baker</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Buy</td>
<td>$12.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Genius Sports. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Genius Sports compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Genius Sports's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Genius Sports's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/GENI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Genius Sports analyst ratings.</strong></a></p>
<h2>All You Need to Know About Genius Sports</h2>
<p>Genius Sports Ltd is a B2B provider of scalable, technology-led products and services to the sports, sports betting, and sports media industries. Its services are organized into three key product areas including Sports Technology and Services; Betting Technology, Content and Services; and Media Technology, Content and Services. All of its products are powered by proprietary technology and robust data infrastructure. It generates maximum revenue from the Betting Technology, Content and Services division. Geographically, the company derives a majority of its revenue from Europe.</p>
<h3>Financial Insights: Genius Sports</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Over the 3M period, Genius Sports showcased positive performance, achieving a revenue growth rate of <strong>20.28%</strong> as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Genius Sports's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-5.69%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Genius Sports's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-1.28%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Genius Sports's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-0.97%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.02</strong>.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


GENI

Forecasting The Future: 6 Analyst Projections For Genius Sports

<p>During the last three months, 5 analysts shared their evaluations of Conmed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Conmed and provided 12-month price targets. The average target is $58.4, accompanied by a high estimate of $61.00 and a low estimate of $55.00. This current average has decreased by 20.44% from the previous average price target of $73.40. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1749733245_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Conmed. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Hold</td>
<td>$61.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$58.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Vik Chopra</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$57.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$61.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$55.00</td>
<td>$75.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Conmed. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Conmed compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Conmed's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Conmed's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CNMD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Conmed analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Conmed</h2>
<p>Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Geographically operates in USA, Europe, Middle East &amp; Africa, Asia Pacific and North America. Majority is revenue is from USA.</p>
<h3>Conmed: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Conmed displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately <strong>2.88%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Conmed's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>1.88%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>0.62%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Conmed's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>0.26%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.91</strong>, Conmed adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CNMD

Demystifying Conmed: Insights From 5 Analyst Reviews

<p>Oppenheimer  analyst Ken Wong   maintains PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) with a Outperform and raises the price target from $170 to $190.</p>


Oppenheimer Maintains Outperform on PTC, Raises Price Target to $190

<p><strong>MercadoLibre's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NYSE">MELI</a>) short percent of float has fallen 3.5% since its last report. The company recently reported that it has <strong>696 thousand shares sold short</strong>, which is 1.38% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.22 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>MercadoLibre Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1749733233_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for MercadoLibre has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing MercadoLibre's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, MercadoLibre's peer group average for short interest as a percentage of float is 10.96%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

MELI

Peering Into MercadoLibre's Recent Short Interest

<p><strong>Stewart Information Servs's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STC#NYSE">STC</a>) short percent of float has fallen 15.87% since its last report. The company recently reported that it has <strong>535 thousand shares sold short</strong>, which is 2.28% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.48 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>Stewart Information Servs Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1749733228_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Stewart Information Servs has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing Stewart Information Servs's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Stewart Information Servs's peer group average for short interest as a percentage of float is 5.73%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Peering Into Stewart Information Servs's Recent Short Interest

<p><strong>Cadence Design Systems's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NYSE">CDNS</a>) short percent of float has fallen 10.12% since its last report. The company recently reported that it has <strong>3.66 million shares sold short</strong>, which is 1.51% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 1.4 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>Cadence Design Systems Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1749733222_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Cadence Design Systems has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing Cadence Design Systems's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Cadence Design Systems's peer group average for short interest as a percentage of float is 2.97%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


CDNS

How Do Investors Really Feel About Cadence Design Systems?

<p>Leveraging our strong cash position and robust business fundamentals, management is actively advancing our innovative treasury management approach by evaluating strategic crypto initiatives and Bitcoin adoption. We are in active discussions with leading crypto industry veterans and thought leaders to provide expert guidance on digital asset opportunities, which will significantly enhance our crypto strategy decision-making capabilities and strengthen our market positioning in the evolving digital asset space. This forward-thinking approach to corporate finance aims to optimize capital allocation and drive long-term shareholder value creation.</p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Prenetics Advances Treasury Strategy With Strategic Crypto Initiatives And Bitcoin Adoption Discussions

<p>During the last three months, 7 analysts shared their evaluations of Universal Technical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UTI#NYSE">UTI</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $36.57, a high estimate of $40.00, and a low estimate of $35.00. This current average reflects an increase of 4.49% from the previous average price target of $35.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1749733217_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Universal Technical. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$36.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Jasper Bibb</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$40.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Eric Martinuzzi</td>
<td>Lake Street</td>
<td>Raises</td>
<td>Buy</td>
<td>$38.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Eric Martinuzzi</td>
<td>Lake Street</td>
<td>Raises</td>
<td>Buy</td>
<td>$35.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$36.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Steve Frankel</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$36.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$35.00</td>
<td>$35.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Universal Technical. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Universal Technical compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Universal Technical's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Universal Technical's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/UTI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Universal Technical analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Universal Technical</h2>
<p>Universal Technical Institute Inc is an educational institution. It provides undergraduate degree, as well as certificate programs for technicians in the automotive, diesel, collision repair, motorcycle and marine fields. The company's reportable segment which includes Universal Technical Institute (UTI) and Concorde Career Colleges, Corporate. Majority of the revenue is generated from UTI segment which provides different kinds of degree and non-degree transportation and skilled trades technical training programs under brands such as Universal Technical Institute, Motorcycle Mechanics Institute, Marine Mechanics Institute and others. It also provides dealer technician training or instructor staffing services to manufacturers.</p>
<h3>Universal Technical's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Universal Technical's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of <strong>12.64%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Universal Technical's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>5.52%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Universal Technical's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>3.99%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.55%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Universal Technical's debt-to-equity ratio surpasses industry norms, standing at <strong>0.87</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Forecasting The Future: 7 Analyst Projections For Universal Technical

Management

VVPR

VivoPower Appoints David Mansfield As CFO

<p>Barclays  analyst Saket Kalia   maintains SailPoint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIL#NASDAQ">SAIL</a>) with a Overweight and raises the price target from $23 to $25.</p>


SAIL

Barclays Maintains Overweight on SailPoint, Raises Price Target to $25

Press Releases

General

Alliance Entertainment Unveils New Handmade by Robots Collectible Figures at Walmart, Tapping into the Booming Pop Culture Market

Earnings

Alliance Entertainment Reports Second Quarter Fiscal Year 2025 Results

Future Today Expands Portfolio with ULTRAMAN, a Sci-Fi and Action-Packed Franchise, from Mill Creek Entertainment

Alliance Entertainment Wins Bid to Acquire Key Assets from Diamond Comic Distributors

Alliance Entertainment Powers Record Store Day 2025 as Premier Distributor of Exclusive Vinyl Releases

Alliance Entertainment to Host Third Quarter Fiscal Year 2025 Results Conference Call on May 15 at 4:30 p.m. Eastern Time

Alliance Entertainment Reports Third Quarter Fiscal Year 2025 Results

Alliance Entertainment Appoints Paramount Veteran Robert Oram as EVP to Accelerate Home Entertainment Expansion

Alliance Entertainment's Handmade by Robots Enters Anime Market with Launch of My Hero Academia Collectibles

Alliance Entertainment Launches Alliance Home Entertainment Division to Drive Future of Film and TV Distribution

AENT

A-Mark Precious Metals, Inc. - Common Stock

A-Mark Precious Metals

BrilliA

Cheetah Net Supply Chain Service Inc. - Class A Common Stock

Cheetah Net Supply Chain

Amcon Distributing

Educational Development Corporation - Common Stock

Educational Development

Epsium Enterprise Limited - Ordinary Shares

Epsium Enterprise

GigaCloud Technology Inc - Class A Ordinary Shares

GigaCloud Tech

Greenlane Holdings, Inc. - Class A Common Stock

Greenlane Hldgs

Genuine Parts

INNEOVA Holdings Limited - Ordinary Shares

INNEOVA Holdings

J-Long Group

Kaival Brands Innovations Group, Inc. - Common Stock

Kaival Brands Innovations

Pool

Raytech Holding Limited - ordinary shares

Raytech Holding

Top Win International Limited - Ordinary Shares

Top Win International

Weyco Group

ThinkEquity

Screenshot 2024-06-24 at 11.09.03 PM

Movers & Shakers

AMZN

TOON

Kartoon Studios Gears Up To Launch Most Ambitious Project Yet With New Winnie-The-Pooh Franchise; Backed By $30M Of Non-Dilutive Financing From Catalyst Venture Partners

Comments

Alliance Entertainment

Notizie

Ultime notizie per Alliance Entertainment (NASDAQ:AENT) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO